secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2023-12-28T23:59:59+00:00
Accession:  0001493152-23-046319
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate faces new Nasdaq delisting notice; halts CTx-1301 Phase 3 trials, plans NDA by H1 2025
--------------------------------------------------------------------------------

- Received additional Nasdaq non-compliance letter on Dec 26 due to three board resignations; hearing set for Feb 2024.
- Stopped enrollment in two Phase 3 pediatric ADHD studies for CTx-1301 after FDA guidance; NDA planned H1 2025 under 505(b)(2).
- Capital needed for CTx-1301 NDA reduced to $17-21M, $9-13M less than prior estimate.
- Needs to raise ~$15M by March 31, 2024 to regain compliance with Nasdaq minimum stockholders' equity rule.
- Board reduced to two non-independent directors; actively seeking new independent directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315223046319/0001493152-23-046319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315223046319/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-046319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer